U.S. markets closed

Xenon Pharmaceuticals Inc. (XENE)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
25.88+0.05 (+0.19%)
At close: 04:00PM EST
25.88 0.00 (0.00%)
After hours: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close25.83
Bid25.91 x 800
Ask32.30 x 1000
Day's Range25.19 - 26.73
52 Week Range10.86 - 36.42
Avg. Volume2,243,303
Market Cap1.38B
Beta (5Y Monthly)1.84
PE Ratio (TTM)N/A
EPS (TTM)-1.66
Earnings DateFeb 28, 2022 - Mar 04, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est45.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for XENE

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Xenon Pharmaceuticals Inc.
    Analyst Report: Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
    Fair Value
    Economic Moat
    23 hours agoMorningstar
View more
  • Benzinga

    Xenon Pharmaceuticals Insider Sold Over $550K In Company Stock

    Simon Pimstone, Insider at Xenon Pharmaceuticals (NASDAQ:XENE), made a large insider sell on November 15, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Monday showed that Pimstone sold 17,557 shares of Xenon Pharmaceuticals at a price of $31.33. The total transaction amounted to $550,061. Pimstone still owns a total of 210,186 shares of Xenon Pharmaceuticals worth, $6,568,312. Xenon Pharmaceuticals shares are trading down 2.31%

  • GlobeNewswire

    Xenon Pharmaceuticals to Participate in Upcoming Investor Conferences

    BURNABY, British Columbia, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that Ian Mortimer, Xenon’s President and Chief Executive Officer, along with Sherry Aulin, Xenon’s Chief Financial Officer, will participate virtually in the following investor conferences: Guggenheim 3rd Annual Neuro/Immunology Conference on Monday, November 15, 2021 (one-on-one meetings only)Stifel 2021 Virtual Healthcare Conferen

  • Zacks

    Xenon Pharmaceuticals (XENE) Reports Q3 Loss, Tops Revenue Estimates

    Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of 18.18% and 4.69%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?